Hepatoblastoma — Trials

Hepatoblastoma — Trials · CancerIndex

Clinical trials

Registered studies

61 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 26
Recruiting: 11
Ph III recruiting: 1
Growth YoY: —
Industry share: 12%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3)

clinicaltrialsPublishedShowing 1–10 of 10 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03213678	Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)	completed	Phase 2	18	National Cancer Institute (NCI)NIH	2	Apr 21, 2026	clinicaltrials
NCT03213665	Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)	completed	Phase 2	20	National Cancer Institute (NCI)